# A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

Source: https://onco.cc/trials/nct01954316/  
OnCo record `nct01954316` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CFI-400945 run by University Health Network, Toronto, completed.

## Summary

A Study of CFI-400945 Fumarate in Patients With Advanced Cancer is a phase 1 interventional study registered as NCT01954316 by University Health Network, Toronto, with 46 participants enrolled, started 2014-03. Conditions recorded: Advanced Cancer. Interventions recorded: CFI-400945.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01954316
- Phase: 1
- Setting: An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer
- Sponsor: University Health Network, Toronto
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT01954316: https://clinicaltrials.gov/study/NCT01954316

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CFI-400945](https://onco.cc/drugs/cfi-400945/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct01954316.json